The burden of neovascular age-related macular degeneration: a patient’s perspective

Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2 1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia Purpose: To quantify the burden and quality of life of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/c574bc2573a74331bfdb03eefea0a587
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c574bc2573a74331bfdb03eefea0a587
record_format dspace
spelling oai:doaj.org-article:c574bc2573a74331bfdb03eefea0a5872021-12-02T08:36:31ZThe burden of neovascular age-related macular degeneration: a patient’s perspective1177-5483https://doaj.org/article/c574bc2573a74331bfdb03eefea0a5872018-12-01T00:00:00Zhttps://www.dovepress.com/the-burden-of-neovascular-age-related-macular-degeneration-a-patients--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2 1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia Purpose: To quantify the burden and quality of life of patients and their caregivers in a cohort of patients with neovascular age-related macular degeneration (nAMD) in an Australian clinical setting.Methods: A total of 103 patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for nAMD were asked to complete questionnaires relating to the financial and time burdens of nAMD.Results: All patients completed the questionnaires. Loss in productivity due to attendance of appointments was 4.4±1.7 hours per month, with additional time lost by caregivers. Financial strain was incurred by direct medical costs associated with intravitreal assessment and injections at an average of AU$199.2±$83.1 per month. Indirect costs incurred averaged $64.8±$79.7 per month. Qualitative indirect costs due to loss of productivity for the patient, unpaid caregivers, and loss of productivity due to premature mortality were also a considerable burden. Overall mean Visual Function Questionnaire and EuroQol 5D-3L scores were correlated with visual acuity and demonstrated patients’ subjective decline in quality of vision.Conclusion: Management of nAMD carries a substantial burden on patients and caregivers. These results provide important information in understanding the effect of anti-VEGF therapy among patients with nAMD. Together with the quality-of-life burden on the patients, the management of nAMD has a significant societal impact. Keywords: burden, treatment, anti-VEGF, age-related macular degeneration, Australia, patient perspectiveSpooner KLMhlanga CTHong THBroadhead GKChang AADove Medical PressarticleBurdentreatmentanti-VEGFage-related macular degenerationAustraliaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 2483-2491 (2018)
institution DOAJ
collection DOAJ
language EN
topic Burden
treatment
anti-VEGF
age-related macular degeneration
Australia
Ophthalmology
RE1-994
spellingShingle Burden
treatment
anti-VEGF
age-related macular degeneration
Australia
Ophthalmology
RE1-994
Spooner KL
Mhlanga CT
Hong TH
Broadhead GK
Chang AA
The burden of neovascular age-related macular degeneration: a patient’s perspective
description Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2 1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia Purpose: To quantify the burden and quality of life of patients and their caregivers in a cohort of patients with neovascular age-related macular degeneration (nAMD) in an Australian clinical setting.Methods: A total of 103 patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for nAMD were asked to complete questionnaires relating to the financial and time burdens of nAMD.Results: All patients completed the questionnaires. Loss in productivity due to attendance of appointments was 4.4±1.7 hours per month, with additional time lost by caregivers. Financial strain was incurred by direct medical costs associated with intravitreal assessment and injections at an average of AU$199.2±$83.1 per month. Indirect costs incurred averaged $64.8±$79.7 per month. Qualitative indirect costs due to loss of productivity for the patient, unpaid caregivers, and loss of productivity due to premature mortality were also a considerable burden. Overall mean Visual Function Questionnaire and EuroQol 5D-3L scores were correlated with visual acuity and demonstrated patients’ subjective decline in quality of vision.Conclusion: Management of nAMD carries a substantial burden on patients and caregivers. These results provide important information in understanding the effect of anti-VEGF therapy among patients with nAMD. Together with the quality-of-life burden on the patients, the management of nAMD has a significant societal impact. Keywords: burden, treatment, anti-VEGF, age-related macular degeneration, Australia, patient perspective
format article
author Spooner KL
Mhlanga CT
Hong TH
Broadhead GK
Chang AA
author_facet Spooner KL
Mhlanga CT
Hong TH
Broadhead GK
Chang AA
author_sort Spooner KL
title The burden of neovascular age-related macular degeneration: a patient’s perspective
title_short The burden of neovascular age-related macular degeneration: a patient’s perspective
title_full The burden of neovascular age-related macular degeneration: a patient’s perspective
title_fullStr The burden of neovascular age-related macular degeneration: a patient’s perspective
title_full_unstemmed The burden of neovascular age-related macular degeneration: a patient’s perspective
title_sort burden of neovascular age-related macular degeneration: a patient’s perspective
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/c574bc2573a74331bfdb03eefea0a587
work_keys_str_mv AT spoonerkl theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT mhlangact theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT hongth theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT broadheadgk theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT changaa theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT spoonerkl burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT mhlangact burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT hongth burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT broadheadgk burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
AT changaa burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective
_version_ 1718398458277134336